Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition

Pinku Mukherjee, Gargi D. Basu, Teresa L. Tinder, Durai B. Subramani, Judy M. Bradley, Million Arefayene, Todd Skaar, Giovanni De Petris

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

With a 5-year survival rate of <5%, pancreatic cancer is one of the most rapidly fatal malignancies. Current protocols for the treatment of pancreas cancer are not as effective as we desire. In this study, we show that a novel Mucin-1 (MUC1)-based vaccine in combination with a cyclooxygenase-2 inhibitor (celecoxib), and low-dose chemotherapy (gemcitabine) was effective in preventing the progression of preneoplastic intraepithelial lesions to invasive pancreatic ductal adenocarcinomas. The study was conducted in an appropriate triple transgenic model of spontaneous pancreatic cancer induced by the KRAS G12D mutation and that expresses human MUC1 as a self molecule. The combination treatment elicited robust antitumor cellular and humoral immune responses and was associated with increased apoptosis in the tumor. The mechanism for the increased immune response was attributed to the down-regulation of circulating prostaglandin E2 and indoleamine 2, 3,-dioxygenase enzymatic activity, as well as decreased levels of T regulatory and myeloid suppressor cells within the tumor microenvironment. The preclinical data provide the rationale to design clinical trials with a combination of MUC1-based vaccine, celecoxib, and gemcitabine for the treatment of pancreatic cancer.

Original languageEnglish
Pages (from-to)216-224
Number of pages9
JournalJournal of Immunology
Volume182
Issue number1
StatePublished - Jan 1 2009

Fingerprint

Combined Vaccines
Celecoxib
gemcitabine
Pancreatic Neoplasms
Mucin-1
Adenocarcinoma
Indoleamine-Pyrrole 2,3,-Dioxygenase
Tumor Microenvironment
Cyclooxygenase 2 Inhibitors
Myeloid Cells
Humoral Immunity
Clinical Protocols
Dinoprostone
Cellular Immunity
Neoplasms
Down-Regulation
Vaccines
Clinical Trials
Apoptosis
Drug Therapy

ASJC Scopus subject areas

  • Immunology
  • Medicine(all)

Cite this

Mukherjee, P., Basu, G. D., Tinder, T. L., Subramani, D. B., Bradley, J. M., Arefayene, M., ... De Petris, G. (2009). Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition. Journal of Immunology, 182(1), 216-224.

Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition. / Mukherjee, Pinku; Basu, Gargi D.; Tinder, Teresa L.; Subramani, Durai B.; Bradley, Judy M.; Arefayene, Million; Skaar, Todd; De Petris, Giovanni.

In: Journal of Immunology, Vol. 182, No. 1, 01.01.2009, p. 216-224.

Research output: Contribution to journalArticle

Mukherjee, P, Basu, GD, Tinder, TL, Subramani, DB, Bradley, JM, Arefayene, M, Skaar, T & De Petris, G 2009, 'Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition', Journal of Immunology, vol. 182, no. 1, pp. 216-224.
Mukherjee P, Basu GD, Tinder TL, Subramani DB, Bradley JM, Arefayene M et al. Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition. Journal of Immunology. 2009 Jan 1;182(1):216-224.
Mukherjee, Pinku ; Basu, Gargi D. ; Tinder, Teresa L. ; Subramani, Durai B. ; Bradley, Judy M. ; Arefayene, Million ; Skaar, Todd ; De Petris, Giovanni. / Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition. In: Journal of Immunology. 2009 ; Vol. 182, No. 1. pp. 216-224.
@article{c7a69c55adc940e0bd11428ff1241078,
title = "Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition",
abstract = "With a 5-year survival rate of <5{\%}, pancreatic cancer is one of the most rapidly fatal malignancies. Current protocols for the treatment of pancreas cancer are not as effective as we desire. In this study, we show that a novel Mucin-1 (MUC1)-based vaccine in combination with a cyclooxygenase-2 inhibitor (celecoxib), and low-dose chemotherapy (gemcitabine) was effective in preventing the progression of preneoplastic intraepithelial lesions to invasive pancreatic ductal adenocarcinomas. The study was conducted in an appropriate triple transgenic model of spontaneous pancreatic cancer induced by the KRAS G12D mutation and that expresses human MUC1 as a self molecule. The combination treatment elicited robust antitumor cellular and humoral immune responses and was associated with increased apoptosis in the tumor. The mechanism for the increased immune response was attributed to the down-regulation of circulating prostaglandin E2 and indoleamine 2, 3,-dioxygenase enzymatic activity, as well as decreased levels of T regulatory and myeloid suppressor cells within the tumor microenvironment. The preclinical data provide the rationale to design clinical trials with a combination of MUC1-based vaccine, celecoxib, and gemcitabine for the treatment of pancreatic cancer.",
author = "Pinku Mukherjee and Basu, {Gargi D.} and Tinder, {Teresa L.} and Subramani, {Durai B.} and Bradley, {Judy M.} and Million Arefayene and Todd Skaar and {De Petris}, Giovanni",
year = "2009",
month = "1",
day = "1",
language = "English",
volume = "182",
pages = "216--224",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "1",

}

TY - JOUR

T1 - Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition

AU - Mukherjee, Pinku

AU - Basu, Gargi D.

AU - Tinder, Teresa L.

AU - Subramani, Durai B.

AU - Bradley, Judy M.

AU - Arefayene, Million

AU - Skaar, Todd

AU - De Petris, Giovanni

PY - 2009/1/1

Y1 - 2009/1/1

N2 - With a 5-year survival rate of <5%, pancreatic cancer is one of the most rapidly fatal malignancies. Current protocols for the treatment of pancreas cancer are not as effective as we desire. In this study, we show that a novel Mucin-1 (MUC1)-based vaccine in combination with a cyclooxygenase-2 inhibitor (celecoxib), and low-dose chemotherapy (gemcitabine) was effective in preventing the progression of preneoplastic intraepithelial lesions to invasive pancreatic ductal adenocarcinomas. The study was conducted in an appropriate triple transgenic model of spontaneous pancreatic cancer induced by the KRAS G12D mutation and that expresses human MUC1 as a self molecule. The combination treatment elicited robust antitumor cellular and humoral immune responses and was associated with increased apoptosis in the tumor. The mechanism for the increased immune response was attributed to the down-regulation of circulating prostaglandin E2 and indoleamine 2, 3,-dioxygenase enzymatic activity, as well as decreased levels of T regulatory and myeloid suppressor cells within the tumor microenvironment. The preclinical data provide the rationale to design clinical trials with a combination of MUC1-based vaccine, celecoxib, and gemcitabine for the treatment of pancreatic cancer.

AB - With a 5-year survival rate of <5%, pancreatic cancer is one of the most rapidly fatal malignancies. Current protocols for the treatment of pancreas cancer are not as effective as we desire. In this study, we show that a novel Mucin-1 (MUC1)-based vaccine in combination with a cyclooxygenase-2 inhibitor (celecoxib), and low-dose chemotherapy (gemcitabine) was effective in preventing the progression of preneoplastic intraepithelial lesions to invasive pancreatic ductal adenocarcinomas. The study was conducted in an appropriate triple transgenic model of spontaneous pancreatic cancer induced by the KRAS G12D mutation and that expresses human MUC1 as a self molecule. The combination treatment elicited robust antitumor cellular and humoral immune responses and was associated with increased apoptosis in the tumor. The mechanism for the increased immune response was attributed to the down-regulation of circulating prostaglandin E2 and indoleamine 2, 3,-dioxygenase enzymatic activity, as well as decreased levels of T regulatory and myeloid suppressor cells within the tumor microenvironment. The preclinical data provide the rationale to design clinical trials with a combination of MUC1-based vaccine, celecoxib, and gemcitabine for the treatment of pancreatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=59849121138&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59849121138&partnerID=8YFLogxK

M3 - Article

C2 - 19109152

AN - SCOPUS:59849121138

VL - 182

SP - 216

EP - 224

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 1

ER -